Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. N-(8-(2-hydroxybenzoyl)amino)caprylate
2. N-(8-(2-hydroxybenzoyl)amino)caprylate Sodium
3. N-snac
4. Snac Sodium
5. Sodium N-(8-(2-hydroxybenzoyl)amino)caprylate
1. 203787-91-1
2. Snac
3. Sodium 8-(2-hydroxybenzamido)octanoate
4. E414
5. Salcaprozate Sodium [usan]
6. Sodium;8-[(2-hydroxybenzoyl)amino]octanoate
7. Octanoic Acid, 8-[(2-hydroxybenzoyl)amino]-, Monosodium Salt
8. Salcaprozate (sodium)
9. Sodium,8-[(2-hydroxybenzoyl)amino]octanoate
10. 1ytw0422yu
11. Sodium 8-[(2-hydroxybenzoyl)amino]octanoate
12. E-414
13. Sodium 8-((2-hydroxybenzoyl)amino)octanoate
14. Salcaprozate Sodium (usan)
15. Octanoic Acid, 8-((2-hydroxybenzoyl)amino)-, Monosodium Salt
16. Sodium Salcaprozate
17. Unii-1ytw0422yu
18. Salcaprozic Acid, Sodium Salt
19. E 414
20. Salcaprozate Sodium, 99%
21. Salcaprozic Acid Sodium Salt
22. Schembl825599
23. Chembl2107027
24. Dtxsid50174306
25. Amy24031
26. Ex-a3434
27. Mfcd00952954
28. Sodium8-(2-hydroxybenzamido)octanoate
29. Ac-31357
30. As-65676
31. P414
32. Hy-114299
33. Cs-0081977
34. Ft-0696582
35. D05787
36. I10998
37. A879665
38. Q27253228
39. Sodium 8-[(2-hydroxyphenyl)formamido]octanoate
40. Octanoic Acid, 8-[(2-hydroxybenzoyl)amino]-, Sodium Salt
41. Sodium,8-[(2-hydroxybenzoyl)amino]octanoate;sodium 8-(2-hydroxybenzamido)octanoate
Molecular Weight | 301.31 g/mol |
---|---|
Molecular Formula | C15H20NNaO4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 9 |
Exact Mass | 301.12900240 g/mol |
Monoisotopic Mass | 301.12900240 g/mol |
Topological Polar Surface Area | 89.5 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 312 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40217
Submission : 2024-07-22
Status : Active
Type : IV
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39651
Submission : 2024-03-14
Status : Active
Type : IV
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40147
Submission : 2024-06-27
Status : Active
Type : IV
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40217
Submission : 2024-07-22
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39651
Submission : 2024-03-14
Status : Active
Type : IV
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40147
Submission : 2024-06-27
Status : Active
Type : IV
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40177
Submission : 2024-07-16
Status : Active
Type : IV
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized, Window of Opportunity (WOO) trial evaluating clinical and biological effects of intratumoral INT230-6 vs. no treatment in early stage breast cancer.
Lead Product(s): Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium
Therapeutic Area: Oncology Brand Name: INT230-6
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Ottawa Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 24, 2021
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Ottawa Hospital
Deal Size : Undisclosed
Deal Type : Agreement
Details : The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized, Window of Opportunity (WOO) trial evaluating clinical and biological effects of intratumoral INT230-6 vs. no treatment in early stage breast cancer...
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 24, 2021
https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination
08 Oct 2024
// PRESS RELEASE
https://en.hengkangpharm.cn/index.php/news/cphi-milan-2024-zhejiang-hengkang-pharm/
Market Place
Reply
01 Apr 2024
Reply
30 Jul 2022
Reply
08 Jul 2022
Reply
29 Sep 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?